Clinical trial · Interventional
Ameliorated Pap Tests and Cervical Cancer Screening Participation
Effects of the Ameliorated Pap Test on Cervical Cancer Screening Participation: a Multicenter Randomized Controlled Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The Pap test plays a crucial role in the early detection of cervical cancer. A pilot single-center randomized controlled trial applied the peak-end concept and added a non-painful step at the end of Pap smear screening, aimed to reduce recalled pain. However, there is still no multicenter study investigating the effect of the modified Pap test on cervical cancer screening participation. The present project is the first multicenter randomized controlled trial to expand the current scope of the peak-end theory into Pap tests and cervical cancer screening participation by adding a non-painful step at the end of Pap smear screening. Our multidisciplinary team (NTUH Pap Study Group) aims to provide innovative, feasible, and low-cost strategies for cervical cancer screening participation.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer Screening | — | UNRESOLVED | — |
| Cervical Cancer Screening Methods | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Modified Pap test | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- Traditional Pap test
- type
- EXPERIMENTAL
- label
- Modified Pap test
- interventionNames
- Procedure: Modified Pap test
Primary outcomes (1)
- measure
- 3-year cervical cancer screening participation
- timeFrame
- 3 years
- description
- Defined as attending a Pap test at any clinic before the end of the 3rd subsequent year following study entry
Secondary outcomes (4)
- measure
- 1-year cervical cancer screening participation
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 25 Years
Show eligibility criteria text
Inclusion Criteria: * Women aged 25 or above Exclusion Criteria: * Ongoing menstruation * Pregnancy * Incapability of understanding the numeric pain scales * Any active cancer at study entry (defined as cancer diagnosed or treated within the previous 6 months, recurrent, regionally advanced or metastatic cancer) * Previous hysterectomy, pelvic surgery, or radiotherapy * Active vaginal or uterus infection * Analgesic use within 24 hours
References
Publications (33)
- BACKGROUNDJhuang JR, Lee WC, Chan CC. A randomized, double-blind water taste test to evaluate the equivalence of taste between tap water and filtered water in the Taipei metropolis. Sci Rep. 2020 Aug 7;10(1):13387. doi: 10.1038/s41598-020-70272-y. PMID 32770131
- BACKGROUNDShih HY, Lee WC. A Five-Region Hypothesis Test for Exposure-Disease Associations. Sci Rep. 2017 Jul 11;7(1):5131. doi: 10.1038/s41598-017-05301-4. PMID 28698548
- BACKGROUNDPlummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry. 2016 Mar-Apr;39:24-31. doi: 10.1016/j.genhosppsych.2015.11.005. Epub 2015 Nov 18. PMID 26719105
- BACKGROUNDSpitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. doi: 10.1001/archinte.166.10.1092. PMID 16717171
- BACKGROUNDChen HC, Wu CH, Lee YJ, Liao SC, Lee MB. Validity of the five-item Brief Symptom Rating Scale among subjects admitted for general health screening. J Formos Med Assoc. 2005 Nov;104(11):824-9. PMID 16496062
- BACKGROUNDChen CJ, Hong MK, Ding DC. Effective reduction in inadequate Pap smears by using a saline-lubricated speculum and two glass slides. Taiwan J Obstet Gynecol. 2020 Nov;59(6):906-909. doi: 10.1016/j.tjog.2020.09.018. PMID 33218410
- BACKGROUNDSandkuhler J, Lee J. How to erase memory traces of pain and fear. Trends Neurosci. 2013 Jun;36(6):343-52. doi: 10.1016/j.tins.2013.03.004. Epub 2013 Apr 18. PMID 23602194
- BACKGROUNDYen HK, Cheng SY, Chiu KN, Huang CC, Yu JY, Chiang CH; NTUH Pap Study Group. Adding a nonpainful end to reduce pain recollection of Pap smear screening: a randomized controlled trial. Pain. 2023 Aug 1;164(8):1709-1717. doi: 10.1097/j.pain.0000000000002897. Epub 2023 Apr 12.